Summary
Eli Lilly and Company (LLY) filed an 8-K on March 13, 2007, reporting on a significant debt offering that closed on March 7, 2007. The company successfully issued and sold a total of $2.5 billion in senior notes across three tranches: $1 billion in 5.20% Notes due 2017, $700 million in 5.50% Notes due 2017, and $800 million in 5.55% Notes due 2037. These notes are governed by an existing Indenture dated February 1, 1991, with Citibank, N.A. as Trustee. This offering provides Lilly with substantial capital, likely for general corporate purposes, research and development, or strategic initiatives, while diversifying its long-term debt structure. The issuance was facilitated by a robust underwriting syndicate led by Credit Suisse Securities (USA) LLC, Deutsche Bank Securities Inc., J.P. Morgan Securities Inc., and Goldman, Sachs & Co. The filing also includes various exhibits such as the Underwriting Agreement, forms of the notes, the Indenture (incorporated by reference), and legal opinions, all integral to detailing the terms and legality of this substantial debt financing. Investors should note the specific interest rates and maturity dates associated with each series of notes, as well as the company's right to redeem them.
Key Highlights
- 1Eli Lilly completed a significant debt offering, raising a total of $2.5 billion.
- 2The offering consisted of three tranches of senior notes: $1 billion of 5.20% Notes due 2017, $700 million of 5.50% Notes due 2027, and $800 million of 5.55% Notes due 2037.
- 3The notes were issued under an existing Indenture dated February 1, 1991, with Citibank, N.A. serving as Trustee.
- 4The offering was underwritten by a syndicate of major financial institutions, including Credit Suisse, Deutsche Bank, J.P. Morgan, and Goldman Sachs.
- 5The filing includes the Underwriting Agreement, forms of the notes, the Indenture, and legal opinions as exhibits.
- 6The company retains the option to redeem the notes, in whole or in part, under specified redemption prices.